Stellar Biotechnologies Acquires Exclusive, Worldwide License to Clostridium Difficile Immunotherapy Technology PORT HUENEME, CA– Stellar Biotechnologies, Inc. (“Stellar” or “the Company”) (OTCQB: SBOTF) (TSX VENTURE: KLH), announced today that the Company has acquired the exclusive, worldwide license to patented technology for the development of human immunotherapies against Clostridium difficile infection (“C. diff”) from the UniversityREAD FULL POSTREAD FULL POST
Subscribe to Live Updates From StockGuru
Email address is required
Invalid email address
Check your inbox now to confirm your subscription.
Oops! You're already subscribed.